Abstract
Tetrachlorido(O,O'-dibutyl-ethylenediamine-N,N'-di-3-propionate)platinum(iv) complex, [PtCl(4)(n-Bu(2)eddp)], was previously found to be effective against fibrosarcoma and glioma cell lines. Here we presented that [PtCl(4)(n-Bu(2)eddp)] strongly reduced the growth of B16 melanoma cells in vitro. Inhibition of cell viability was accompanied with induction of both necrotic and apoptotic cell death. In addition, [PtCl(4)(n-Bu(2)eddp)] concealed the expansion of tumors induced in syngeneic C57Bl/6 mice without visible signs of nephrotoxicity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Cell Cycle / drug effects
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cisplatin / pharmacology
-
Drug Screening Assays, Antitumor
-
Melanoma, Experimental / drug therapy*
-
Mice
-
Mice, Inbred C57BL
-
Organoplatinum Compounds / pharmacology*
-
Organoplatinum Compounds / therapeutic use
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
tetrachlorido(O,O'-dibutyl-ethylenediamine-N,N'-di-3-propionate)platinum(IV)
-
Cisplatin